Literature DB >> 12614625

Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.

Tobin J Cammett1, Li Luo, Zheng-yu Peng.   

Abstract

Cyclin-dependent kinase inhibitor p16(INK4a) is the founding member of the INK4 family of tumor suppressors capable of arresting mammalian cell division. Missense mutations in the p16(INK4a) gene (INK4a/CDKN2A/MTS1) are strongly linked to several types of human cancer. These mutations are evenly distributed throughout this small, ankyrin repeat protein and the majority of them disrupt the native secondary and/or tertiary structure, leading to protein unfolding, aggregation and loss of function. We report here the use of multiple stabilizing substitutions to increase the stability of p16(INK4a) and furthermore, to restore Cdk4 binding activity of several defective, cancer-related mutant proteins. Stabilizing substitutions were predicted using four different techniques. The three most effective substitutions were combined to create a hyperstable p16(INK4a) variant that is 1.4 kcal/mol more stable than wild-type. This engineered construct is monomeric in solution with wild-type-like secondary and tertiary structure and cyclin-dependent kinase 4 binding activity. Interestingly, these hyperstable substitutions, when combined with oncogenic mutations R24P, P81L or V126D, can significantly restore Cdk4 binding activity, despite the divergent features of each destabilizing mutation. Extensive biophysical studies indicate that the hyperstable substitutions enhance the binding activity of mutant p16 through several different mechanisms, including an increased amount of secondary structure and thermostability, reduction in exposed hydrophobic surface(s) and/or a reduced tendency to aggregate. This apparent global suppressor effect suggests that increasing the thermodynamic stability of p16 can be used as a general strategy to restore the biological activity to defective mutants of this important tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614625     DOI: 10.1016/s0022-2836(03)00043-3

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

Review 1.  The ankyrin repeat as molecular architecture for protein recognition.

Authors:  Leila K Mosavi; Tobin J Cammett; Daniel C Desrosiers; Zheng-Yu Peng
Journal:  Protein Sci       Date:  2004-06       Impact factor: 6.725

2.  In silico protein design by combinatorial assembly of protein building blocks.

Authors:  Hui-Hsu Gavin Tsai; Chung-Jung Tsai; Buyong Ma; Ruth Nussinov
Journal:  Protein Sci       Date:  2004-10       Impact factor: 6.725

3.  Contributions of conserved TPLH tetrapeptides to the conformational stability of ankyrin repeat proteins.

Authors:  Yi Guo; Chunhua Yuan; Feng Tian; Kun Huang; Christopher M Weghorst; Ming-Daw Tsai; Junan Li
Journal:  J Mol Biol       Date:  2010-04-14       Impact factor: 5.469

4.  The crystal structure of a partial mouse Notch-1 ankyrin domain: repeats 4 through 7 preserve an ankyrin fold.

Authors:  Olga Y Lubman; Raphael Kopan; Gabriel Waksman; Sergey Korolev
Journal:  Protein Sci       Date:  2005-03-31       Impact factor: 6.725

5.  Engineering Proteins for Thermostability with iRDP Web Server.

Authors:  Priyabrata Panigrahi; Manas Sule; Avinash Ghanate; Sureshkumar Ramasamy; C G Suresh
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

6.  A method for rapid high-throughput biophysical analysis of proteins.

Authors:  Albert Perez-Riba; Laura S Itzhaki
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.996

7.  A Novel Kleefstra Syndrome-associated Variant That Affects the Conserved TPLX Motif within the Ankyrin Repeat of EHMT1 Leads to Abnormal Protein Folding.

Authors:  Patrick R Blackburn; Alexander Tischer; Michael T Zimmermann; Jennifer L Kemppainen; Sujatha Sastry; Amy E Knight Johnson; Margot A Cousin; Nicole J Boczek; Gavin Oliver; Vinod K Misra; Ralitza H Gavrilova; Gwen Lomberk; Matthew Auton; Raul Urrutia; Eric W Klee
Journal:  J Biol Chem       Date:  2017-01-05       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.